Lettmann Jason sold 2,230 shares of ALX ONCOLOGY HOLDINGS INC at $1.93 for −$4.30k on Aug 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
CHIEF EXECUTIVE OFFICER
CHIEF EXECUTIVE OFFICER
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$4,303.90Shares × reported price
Shares traded
2,230Common Stock
Price per share
$1.93Reported price. Read footnotes for ranges.
% of reported position traded
0.75%This security and ownership context
Holdings after
294,379Direct
Trade date
Aug 17, 2026Sell
Filed
Aug 18, 2026, 5:51 PM ET1-day reporting delay
Accession
0001193125-26-355764Code S · Transaction 3900
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 296,609 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ALXO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ALXO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +1%1w ago −1%1d ago −5.8%
Returns since7d −3.4%30d −16%90d180d1y

Footnotes in full

F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2: Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.